Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Report and Forecast 2024-2032

Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Outlook

The global Alpha-1 Antitrypsin Deficiency (AATD) Treatment market is expected to grow at a CAGR of 9.5% during the period 2024-2032. The prevalence is nearly 0.025% in general population. Asia has comparatively less incidence of AATD as compared to Europe or North American population. North America and Europe are likely to be key markets.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Market Likely to be Driven by Advantages Offered by the Need to Effectively Treat Alpha-1 antitrypsin deficiency (AATD)

Alpha-1 antitrypsin deficiency (AATD) is a genetic illness, and may cause severe lung or liver disease. Symptoms may include trouble breathing and jaundiced, or yellow, skin.

Complications of Alpha-1 antitrypsin deficiency (AATD) depend on the disease it causes. These may include: lungs [if lung disease is developed, complications may include emphysema or bronchiectasis (damage to airway walls in the lungs)], liver (if liver disease is causes, symptoms may include swelling of abdomen and legs, higher risk of infections, or developing liver scarring or cancer), skin (in rare cases, a skin disease called panniculitis may develop; the condition may cause painful red lumps on the skin; the lumps may break open and release liquid or pus).

Augmentation therapy is the only particular therapy for alpha-1 antitrypsin deficiency (AATD); during the therapy, preparations of alpha-1 antitrypsin protein isolated from pooled blood of healthy donors are administered by way of weekly intravenous infusion. This raises the blood levels of alpha-1 antitrypsin deficiency AATD to levels protective for the lung. Studies report that augmentation therapy helps preserve lung function and reduces the number and severity of lung infections. While there is no cure for alpha-1 antitrypsin deficiency (AATD), the lung diseases that it causes can be treated. Treatment includes bronchodilators (enable easier breathing by relaxing the muscles surrounding the airways; short-acting bronchodilators last about four to six hours and are used as required; long-acting bronchodilators last twelve hours or more and may be used every day), inhaled corticosteroid medications (help decrease inflammation of the airways, enabling easy breathing), antibiotics, flu and pneumococcal vaccines, and surgery and other treatments (in advanced cases of disease, surgical options may be considered, such as lung volume reduction surgery and bullectomy). Along with treatment and medication, lifestyle changes may also be recommended, including exercise, training in managing the condition, and nutritional and psychological counselling.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Segmentation

By product, the market is segmented into:

• Bronchodilators
• Oxygen Therapy
• Augmentation Therapy
• Corticosteroids

By route of administration, the market is classified into:

• Injection
• Oral
• Inhalation

By application, the market is divided into:

• Specialty Clinics
• Hospitals
• Pharmacies

By region, the market is segmented into:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the global Alpha-1 Antitrypsin Deficiency (AATD) Treatment market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Grifols, S.A.
• CSL Behring
• Takeda Pharmaceutical Company Limited
• Kamada Ltd
• Arrowhead Pharmaceuticals, Inc.
• Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report